Cargando…
Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib
BACKGROUND: This work set out to examine the hematological adverse events (AEs) of an individualized starting dose (ISD) of niraparib in Chinese patients with ovarian cancer (OC). METHODS: The medical records of 43 patients with OC who were treated with an ISD of niraparib at the Cancer Hospital of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184470/ https://www.ncbi.nlm.nih.gov/pubmed/34164503 http://dx.doi.org/10.21037/atm-21-2252 |